The Evolving Treatment Landscape of Advanced Renal Cell Carcinoma in Patients Progressing after VEGF Inhibition

Despite significant changes in the therapeutic landscape of renal cell carcinoma, the majority of patients with metastatic disease eventually progress after first-line treatment with vascular endothelial growth factor receptors (VEGFR) tyrosine kinase inhibitor (TKI) therapy. Understanding existing...

Descripción completa

Detalles Bibliográficos
Autores principales: Barata, Pedro C., Ornstein, Moshe C., Garcia, Jorge A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Codon Publications 2017
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5515898/
https://www.ncbi.nlm.nih.gov/pubmed/28725539
http://dx.doi.org/10.15586/jkcvhl.2017.69

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5515898/
https://www.ncbi.nlm.nih.gov/pubmed/28725539
http://dx.doi.org/10.15586/jkcvhl.2017.69

Ejemplares similares